Introduction {#s1}
============

Since the 1970s, coronary heart disease (CHD) mortality in England has fallen by a remarkable 60%, with accelerated reductions in annual death rates since 2000 [@pmed.1001237-Bajekal1]. However, CHD remains the leading cause of mortality and is a major contributor to social inequalities in premature mortality in England, as in the USA [@pmed.1001237-The1],[@pmed.1001237-Leyland1]. Moreover, UK death rates have fallen faster in the most socially advantaged groups compared to the most deprived [@pmed.1001237-Bajekal1]. Thus, whilst absolute inequalities in mortality have fallen, relative inequalities have increased over the last decade. Previous country-level analyses have shown that about 50%--70% of the dramatic falls in CHD mortality between 1980 and 2000 were explained by improvements in modifiable risk factors (mainly smoking, total cholesterol and blood pressure), with the remaining 30%--50% attributable to improved uptake of evidence-based treatments [@pmed.1001237-Unal1]--[@pmed.1001237-Wijeysundera1]. However, so far no study has examined the specific contribution of risk factors and medical treatments to the underlying social differentials in CHD mortality falls.

The most recent study in the UK modelled CHD mortality change in England and Wales between 1981 and 2000 [@pmed.1001237-Unal1]. Since then several initiatives have been rolled out to improve the delivery of health care in England. Notable among them include the National Service Framework for CHD (2000) and the Qualities and Outcome Framework (2004), which aim to monitor and incentivise improvements in the quality of services provided for CHD prevention, diagnosis, treatment, and rehabilitation [@pmed.1001237-Department1],[@pmed.1001237-The2]. In addition, important population-wide public health measures to reduce risk factors across the entire population were introduced. These measures included the ban on tobacco advertising (2003); comprehensive smoke-free legislation (2007), and voluntary agreements to reduce salt and artificial trans-fats in processed food [@pmed.1001237-UK1],[@pmed.1001237-UK2]. Reducing health inequalities was at the heart of New Labour\'s health agenda when it came to office in 1997. However, the target to reduce the inequality gap in life expectancy by 2010 was not met [@pmed.1001237-House1]. Furthermore, the potential effect of population-wide interventions on reducing inequalities in CHD mortality (when compared with individual treatments) remains unclear [@pmed.1001237-Capewell1].

Thus although our analysis covers a relatively short period of time, the period included a raft of measures specifically aimed to improve outcomes and reduce social inequalities. We have quantified the variation by socioeconomic circumstances (SEC) in the relative contributions of modifiable population-level risk factors and evidence-based individual treatments to the fall in CHD mortality during the period 2000 to 2007. To do this we have used the widely used and replicated IMPACT model, substantially extending the model to capture socioeconomic inequalities concealed within the overall national trends.

Methods {#s2}
=======

IMPACT~SEC~ Model and Data Sources {#s2a}
----------------------------------

IMPACT is an epidemiological model used to explain the contributions of population-level risk factor changes (incidence reduction) and uptake of evidence-based treatments (case fatality reduction) to the change in CHD deaths between two points in time. This deterministic, cell-based model has been described in detail elsewhere [@pmed.1001237-Unal1],[@pmed.1001237-Ford1]. The extended IMPACT~SEC~ model included all the major risk factors for CHD: smoking, systolic blood pressure, total cholesterol, body mass index (BMI), diabetes, physical inactivity, along with fruit and vegetable consumption; plus all 45 medical and surgical treatments currently in use in nine patient groups. The model included the total population of England aged 25 y and over in 2000 and 2007.

Data sources specific to the England population were used to construct the IMPACT~SEC~ model. When several sources were available, we chose the most up-to-date, representative dataset that we could link to a small-area deprivation index. Population estimates and CHD death counts (2000: ICD9 410--414; 2007: ICD10 I20--I25) by sex, 5-y age bands to age 85+, and deprivation quintile were obtained from the Office for National Statistics. Emergency admissions for acute myocardial infarction were extracted from Hospital Episode Statistics and supplemented with data from the Myocardial Ischaemia National Audit Project to disaggregate ST-elevated acute myocardial infarction and non--ST-elevated acute coronary syndrome, and to apportion treatment uptake to each group. For heart failure admissions, the National Health Service (NHS) Heart Failure Survey was used to estimate in-hospital treatment uptake. The General Practice Research Database and the Health Survey for England provided data on treatment uptake in the community. Risk factor trend data came from the Health Survey for England.

Detailed information on the IMPACT~SEC~ model, calculation methods, and data sources are provided as supporting information in [Text S1](#pmed.1001237.s001){ref-type="supplementary-material"}.

Stratifying Data according to Socioeconomic Circumstances {#s2b}
---------------------------------------------------------

Only the Health Survey for England consistently recorded individual socioeconomic position; but all data sources recorded individual\'s postcode of residence. We therefore used a measure of relative area deprivation as a proxy indicator of the SECs of individuals living in small areas (*n* = 32,482; average population of 1,500). We used the Index of Multiple Deprivation 2007 [@pmed.1001237-Department2] to rank all lower super output areas in England in ascending order of increasing deprivation and grouped them into equal quintiles. Although scoring low on the deprivation index does not necessarily equate to affluence, to assist readability we refer to quintile one as "most affluent" and quintile five as "most deprived." On the basis of postcode of residence, the data providers matched CHD deaths and treated patients to their corresponding deprivation quintile before releasing the data to us.

Deaths Prevented or Postponed {#s2c}
-----------------------------

The total number of deaths prevented or postponed (DPPs) for each deprivation quintile were calculated as the difference between observed deaths in 2007 and expected deaths had age-, sex-, and quintile- specific CHD mortality rates in 2000 remained unchanged. DPPs explained by the model could be positive (i.e., deaths averted) or negative (i.e., additional deaths in 2007 relative to 2000). Any shortfalls between the DPPs explained by the model and the total DPPs for each SEC quintile were assumed to reflect either imprecision in our model parameters or omission of other, unmeasured risk factors.

Mortality Reductions Attributable to Treatment Uptake {#s2d}
-----------------------------------------------------

The treatment component of IMPACT~SEC~ included nine mutually exclusive CHD patient groups: ST-elevation myocardial infarction; non--ST-elevation acute coronary syndrome; secondary prevention post myocardial infarction; secondary prevention post revascularisation; chronic stable coronary artery disease; heart failure patients admitted to hospital; heart failure patients resident in the community; persons in the community taking blood pressure lowering medication; and persons in the community taking lipid lowering treatment. A total of 45 patient-treatment pairings were generated. To avoid double counting of patients treated for two or more conditions within the year (e.g., heart failure develops within 1 y after myocardial infarction in approximately 30% of survivors), we quantified overlaps between different groups and made appropriate adjustments to construct distinct, non-overlapping CHD patient subgroups ([Text S1](#pmed.1001237.s001){ref-type="supplementary-material"}, Table N).

The numbers eligible for treatment, uptake of specific treatment, 1-y case fatality rates, and relative risk reduction due to treatment, all stratified by age, sex, and CHD patient subgroups, were extracted from relevant data sources ([Text S1](#pmed.1001237.s001){ref-type="supplementary-material"}, Tables A, B, F, G, I, J). Disease prevalence and treatment uptake were further stratified by deprivation quintiles.

The estimates of medication uptake in the community recorded in our primary data sources were adjusted to reflect ordinary clinical practice. We assumed that medication adherence (i.e., the proportion of eligible patients actually taking therapeutically effective levels of medication) was 100% among hospitalised patients, 70% among symptomatic patients in the community, and 50% among asymptomatic patients in the community [@pmed.1001237-Ford1]. The scale of the downward adjustment of uptake was assumed to reasonably represent the combined effects of lower rates of adherence in community settings and reduced population effectiveness in routine health care settings compared to optimal clinical trial conditions. Uncertainty in both of these input variables---the actual uptake rates and the adjustment factor---were included in the stochastic sensitivity analysis reported below.

Deaths prevented by each intervention were then calculated by multiplying the numbers of patients in each diagnostic group by the (adherence-adjusted) proportion of those patients who received the treatment, the baseline case fatality rate, and the relative risk reduction of that treatment. To estimate the cumulative effect of relative risk reduction for patients on a combination of drug therapies, we used the Mant and Hicks correction [@pmed.1001237-Mant1].

Many of the treatments were already widely used in 2000. The net benefit of an intervention in 2007 was therefore calculated by subtracting the expected number of deaths prevented if 2000 uptake rates had remained unchanged from the deaths prevented using 2007 treatment uptake rates.

Mortality Reductions Attributable to Risk Factor Changes {#s2e}
--------------------------------------------------------

We included seven risk factors in the model; both behavioural---smoking, physical inactivity, fruit and vegetable consumption, BMI---and physiological markers including systolic blood pressure, total serum cholesterol, and diagnosed diabetes. To quantify the mortality benefits of an absolute change in each specific risk factor between 2000 and 2007, we used two approaches: a regression-based approach for factors measured on a continuous scale (e.g., total blood cholesterol); and, a population-attributable risk fraction approach for dichotomous variables such as diagnosed diabetes. The independent regression coefficients of mortality benefit for a unit change in mean risk factor were obtained from published multivariate analyses ([Text S1](#pmed.1001237.s001){ref-type="supplementary-material"}, Table I). Hence, the contribution of each risk factor to deaths averted was then calculated as the product of the deaths in 2000 (the base year), the absolute change in risk factor, and the associated relative risk reduction. For binary variables, we used relative risks from the most recent meta-analyses and population cohort studies ([Text S1](#pmed.1001237.s001){ref-type="supplementary-material"}, Table J).

CHD deaths are usually caused by multiple risk factors acting simultaneously. It is therefore recommended that enumerating mortality benefits from risk factor reductions should not use a simple additive approach. Instead, the effects of risk factor changes should be jointly estimated using the cumulative risk-reduction approach. This can be stated in the equation:The cumulative effect of change in all risk factors over the study period was calculated by age, sex, and deprivation quintile (see [Text S1](#pmed.1001237.s001){ref-type="supplementary-material"}, Section 1.3). The ratio of the cumulative effect to the corresponding additive effect was then calculated, yielding 70 adjustment factors ([Text S1](#pmed.1001237.s001){ref-type="supplementary-material"}, Table D). These adjustment factors were used to scale down the additive DPPs for each risk factor. These adjusted DPPs, summed over all seven risk factors, then equalled the estimated total combined DPPs, capturing the multiplicative net impact of positive and adverse changes in risk factors. All risk factor DPPs quoted in the results tables refer to the adjusted DPPs.

We assumed that there was no further synergy between the treatment and risk-factor components of the model. Lag times between the change in cardiovascular risk factor levels and change in CHD mortality rates were assumed to be relatively rapid [@pmed.1001237-Kuulasmaa1] and were therefore not specifically modelled. Similar to economic evaluation studies in health [@pmed.1001237-Barendregt1], 95% uncertainty intervals around the model output (i.e., DPPs) were calculated using Monte Carlo simulation. This calculation involved replacing all fixed input parameters used in the model by appropriate probability distributions, and repeatedly recalculating the model output with values sampled from the defined input distributions ([Text S1](#pmed.1001237.s001){ref-type="supplementary-material"}, Table M). We used the EXCEL add-in Ersatz software ([www.epigear.com](http://www.epigear.com)) to perform 1,000 runs to determine the 95% uncertainty intervals of the DPPs (2.5th and 97.5th percentile values corresponding to the lower and upper limits).

Results {#s3}
=======

Between 2000 and 2007, the age-standardised CHD mortality rate in adults aged 25 y and over fell from 229 to 147 deaths per 100,000; a decline of 36% overall or 6.1% per year ([Table 1](#pmed-1001237-t001){ref-type="table"}). In 2007, there were 74,174 CHD deaths, 56% of these were in men. Both death rates and the number of deaths were lowest in the most affluent quintile and the pace of fall was also faster: decreasing by 6.7% per year compared to just 4.9% in the most deprived quintile. Differentials in the rates of fall therefore widened relative inequalities over the period.

10.1371/journal.pmed.1001237.t001

###### Observed coronary heart disease deaths, age-standardised rates 2000 and 2007 and deaths prevented or postponed in England and stratified by deprivation quintiles.

![](pmed.1001237.t001){#pmed-1001237-t001-1}

  Adults Aged 25 and over                            England   Most Affluent   IMDQ2    IMDQ3    IMDQ4    Most Deprived
  ------------------------------------------------- --------- --------------- -------- -------- -------- ---------------
  Population (000s)                                                                                      
  2000                                               33,952        6,972       7,035    6,939    6,678        6,329
  2007                                               35,281        7,328       7,363    7,233    6,906        6,451
  Observed deaths                                                                                        
  2000                                               103,243      16,529       19,827   21,460   22,187      23,240
  2007                                               74,174       12,312       14,444   15,347   15,676      16,395
  Age-standardised rates (per 100,000)                                                                   
  2000                                                 229          177         199      222      257          306
  2007                                                 147          109         124      141      169          215
  Annual percent fall                                  6.1          6.7         6.5      6.3      5.8          4.9
  Expected deaths 2007 (had 2000 rates persisted)    112,244      19,665       22,669   23,696   23,260      22,953
  DPP (Expected - observed deaths, 2007)             38,070        7,353       8,225    8,349    7,584        6,558
  Percent expected deaths averted                     33.9         37.4         36.3     35.2     32.6        28.6

Rates have been standardised to the European Union reference population aged 25 and over. Separate breakdowns for males and females are available in [Text S1](#pmed.1001237.s001){ref-type="supplementary-material"}, Table E.

IMD, index of multiple deprivation.

Nationally, there were 38,070 fewer CHD deaths in 2007 than if 2000 mortality rates had persisted, representing the "total" DPPs. Despite the slower annual rates of fall in the most deprived quintile, their higher CHD mortality rates in the base year meant that the number of DPPs by 2007 were fairly equally distributed: about 6,560 fewer deaths in the most deprived quintile versus 7,355 in the most affluent ([Table 1](#pmed-1001237-t001){ref-type="table"}).

Overall, approximately half of the total CHD mortality fall (19,780 fewer deaths or 52%; 95% uncertainly interval ranging from 40% to 70%) was attributable to improvements in uptake of medical and surgical treatments ([Table 2](#pmed-1001237-t002){ref-type="table"}). In contrast, population-level risk factor changes accounted for approximately 12,990 (34%; 21%--47%) fewer deaths ([Table 3](#pmed-1001237-t003){ref-type="table"}). The model could not explain some 14% of the overall mortality fall (i.e., a shortfall of 5,300 deaths) ([Figure 1](#pmed-1001237-g001){ref-type="fig"}; [Table 3](#pmed-1001237-t003){ref-type="table"}). The contribution of medical treatments to the deaths averted was very similar across all quintiles, ranging from 50% in the most affluent quintile to 53% in the most deprived ([Table 4](#pmed-1001237-t004){ref-type="table"}). But risk factor changes explained a smaller proportion of deaths prevented in the most affluent quintile compared with the most deprived (approximately 29% versus 44%, respectively). As a result, about 21% of CHD deaths prevented could not be explained by the model in the most affluent quintile. The proportion not explained fell successively with increasing deprivation to 3% of CHD deaths (190 deaths) not explained in the most deprived quintile.

![Proportion of coronary heart disease mortality decline attributable to treatment or risk factor changes, 2000--2007.\
England overall and by socioeconomic quintile.](pmed.1001237.g001){#pmed-1001237-g001}

10.1371/journal.pmed.1001237.t002

###### Coronary heart disease deaths prevented or postponed due to changes in treatment uptake between 2000 and 2007 in England and stratified by deprivation quintiles.

![](pmed.1001237.t002){#pmed-1001237-t002-2}

  Treatment by Patient Groups                                                         England: DPP   By IMD: DPP                                                                            
  ---------------------------------------------------------------------------------- -------------- ------------- ------------ ------------ ----------- ----------- ----------- ----------- -----------
  **STEMI** [b](#nt105){ref-type="table-fn"}                                            **−130**      **−0.3**     ***−0.8***   ***0.5***     **−6**      **−27**     **−28**     **−31**     **−38**
  Thrombolysis                                                                            −118                                                  −22         −23         −21         −23         −29
  Aspirin                                                                                  24                                                    5           4           5           3           7
  B-blocker                                                                                4                                                     1           0           1           1           2
  ACE inhibitor or ARB                                                                     5                                                     0           0           2           1           2
  Clopidogrel                                                                              65                                                   12          14          14          13          12
  Primary PCI                                                                             139                                                   30          28          28          27          25
  Primary CABG                                                                             1                                                     0           0           0           0           0
  CPR in hospital[c](#nt106){ref-type="table-fn"}                                         −252                                                  −33         −51         −57         −53         −57
  **NSTEACS** [b](#nt105){ref-type="table-fn"}                                          **295**        **0.8**     ***0.0***    ***2.2***     **57**      **59**      **62**      **53**      **65**
  Aspirin and heparin                                                                     341                                                   54          68          68          63          88
  Aspirin alone                                                                           −114                                                  −15         −24         −21         −21         −31
  PG IIB/IIIA inhibitors                                                                   −1                                                   −2          −1           0           0           2
  ACE inhibitor or ARB                                                                     44                                                    6           8           9          10          10
  B-blocker                                                                                27                                                    5           5           6           5           6
  Clopidogrel                                                                             203                                                   36          40          46          41          40
  CABG surgery                                                                             1                                                     2           1           0           0          −1
  PCI                                                                                      54                                                   11          10          12          12          10
  CPR in hospital[c](#nt106){ref-type="table-fn"}                                         −259                                                  −40         −48         −58         −55         −58
  **Secondary prevention post MI** [b](#nt105){ref-type="table-fn"}                    **3,510**       **9.2**     ***7.2***    ***11.4***    **640**     **775**     **746**     **711**     **639**
  Aspirin                                                                                 351                                                   65          69          76          87          55
  B-blocker                                                                               862                                                   158         197         194         167         146
  ACE inhibitor or ARB                                                                    903                                                   166         200         190         175         172
  Statin                                                                                 1,303                                                  241         280         269         268         245
  Warfarin                                                                                 92                                                    8          30          17          15          21
  Rehabilitation[d](#nt107){ref-type="table-fn"}                                           0                                                     0           0           0           0           0
  **Secondary prevention post revascularisation** [b](#nt105){ref-type="table-fn"}      **590**        **1.5**     ***1.2***    ***1.9***     **112**     **121**     **128**     **117**     **110**
  Aspirin                                                                                  45                                                   10          10          11           8           7
  B-blocker                                                                               154                                                   29          31          34          31          30
  ACE inhibitor or ARB                                                                    179                                                   35          37          37          34          36
  Statin                                                                                  174                                                   31          36          38          37          32
  Warfarin                                                                                 0                                                     0           0           1           0          −1
  Rehabilitation (post CABG)[d](#nt107){ref-type="table-fn"}                               0                                                     0           0           0           0           0
  Rehabilitation (post PTCA)                                                               36                                                    7           7           7           7           7
  **Chronic stable CAD** [b](#nt105){ref-type="table-fn"}                              **4,835**      **12.7**     ***9.6***    ***16.8***    **851**    **1,007**   **1,015**   **1,016**    **955**
  Aspirin in community                                                                    818                                                   139         159         176         179         165
  Statin in community                                                                    2,488                                                  443         523         526         510         485
  ACE inhibitor or ARB                                                                   1,292                                                  241         281         268         261         241
  CABG surgery                                                                            236                                                   27          44          45          57          63
  **Heart failure - hospital** [b](#nt105){ref-type="table-fn"}                         **250**        **0.7**     ***0.5***    ***0.8***     **42**      **47**      **53**      **59**      **51**
  ACE inhibitor                                                                            49                                                    8           9          10          10          11
  B-blocker                                                                                39                                                    6           8           8           9           9
  Spironolactone                                                                           37                                                    6           7           8           8           8
  Aspirin                                                                                 126                                                   21          22          27          32          23
  **Heart failure - community** [b](#nt105){ref-type="table-fn"}                       **3,335**       **8.8**     ***7.3***    ***10.4***    **564**    **689v**     **732**     **711**     **641**
  ACE inhibitor or ARB                                                                    737                                                   125         158         171         146         137
  B-blocker                                                                              1,592                                                  284         325         353         338         292
  Spironolactone                                                                          617                                                   105         134         120         129         129
  Aspirin                                                                                 389                                                   50          72          88          97          83
  **Hypertension treatment** [b](#nt105){ref-type="table-fn"}                          **1,800**       **4.7**     ***1.8***    ***9.9***     **357**     **411**     **408**     **345**     **277**
  **Hyperlipidemia treatment (statins)** [b](#nt105){ref-type="table-fn"}              **5,300**      **13.9**     ***5.0***    ***31.8***   **1,054**    **975**    **1,305**   **1,194**    **772**
  **[Total treatment contribution]{.ul}** [b](#nt105){ref-type="table-fn"}             **19,780**     **52.0**     ***40.2***   ***69.7***   **3,670**   **4,055**   **4,420**   **4,166**   **3,471**

Subtotals for England (column 1) have been rounded to nearest 5.

The 95% uncertainty interval corresponds to the lower (2.5th percentile) and upper (97.5th percentile) limits of the uncertainty analysis. These are shown to indicate range around the central estimate of percent of DPPs explained (column 3).

Sub-totals (in rows) for CHD patient groups.

We have assumed no change in cardiopulmonary resuscitation (CPR) uptake in the community between 2000 and 2007. Their contribution to DPPs have therefore been set to zero.

No change in uptake between 2000 and 2007.

Abbreviations: B-blocker, beta-blocker; CABG, coronary artery bypass graft; CAD, coronary artery disease; IMD, index of multiple deprivation; MI, myocardial infarction; NSTEACS, non-ST elevation acute coronary syndrome; PCI, percutaneous coronary intervention; PG, platelet glycoprotein; PTCA, percutaneous transluminal coronary angioplasty; STEMI, ST elevation myocardial infarction.

10.1371/journal.pmed.1001237.t003

###### CHD deaths prevented or postponed due to changes in risk factor prevalence between 2000 and 2007 in England and stratified by deprivation quintiles.

![](pmed.1001237.t003){#pmed-1001237-t003-3}

  Risk Factors                                                          England: DPP   By IMD: DPP                                                  
  -------------------------------------------------------------------- -------------- ------------- ------- ------- ------- ------- ------- ------- -------
  **Current smoking**                                                      1,040           2.7        0.1     5.6     93      148     189     242     368
  **Physical inactivity**                                                   600            1.6        0.8     2.3     91      109     119     130     155
  **Systolic blood pressure, mmHg** [b](#nt111){ref-type="table-fn"}       11,160         29.3       18.4    40.0    1,861   2,168   2,321   2,391   2,421
  **Total cholesterol, mmol/l** [c](#nt112){ref-type="table-fn"}           2,090           5.5        3.0     8.3     232     498     287     351     722
  **Fruit and vegetable consumption**                                      1,555           4.1        1.1     8.3     305     334     342     301     273
  **BMI**                                                                   −640          −1.7       −2.9    −0.4    −111    −129    −135    −133    −135
  **Diabetes**                                                             −2,820         −7.4       −12.6   −2.5    −365    −438    −533    −577    −908
  **Total risk factors contribution**                                      12,990         34.1       21.1    47.3    2,107   2,690   2,591   2,704   2,896
  **Total treatment contribution** [d](#nt113){ref-type="table-fn"}        19,780         52.0       40.2    69.7    3,670   4,055   4,420   4,166   3,471
  **DPPs explained by model**                                              32,770         86.1       64.8    107.3   5,777   6,746   7,012   6,870   6,367
  **DPPs not explained**                                                   5,300          13.9                       1,576   1,479   1,337    714     191
  **Total DPPs**                                                           38,070          100                       7,353   8,225   8,349   7,584   6,558

Subtotals for England (column 1) have been rounded to nearest 5.

The 95% uncertainty interval corresponds to the lower (2.5th percentile) and upper (97.5th percentile) limits of the uncertainty analysis.

After subtracting DPPs due to hypertension treatment in primary prevention.

After subtracting DPPs due to statin treatment in primary prevention.

See [Table 2](#pmed-1001237-t002){ref-type="table"} for detailed breakdown by patient group and treatment type.

Abbreviations: IMD, index of multiple deprivation.

10.1371/journal.pmed.1001237.t004

###### Percentage distribution of deaths prevented of postponed by deprivation quintile.

![](pmed.1001237.t004){#pmed-1001237-t004-4}

  Treatments by Patient Groups; Risk Factors                                                                   England      Most Affluent      IMDQ2         IMDQ3         IMDQ4      Most Deprived
  --------------------------------------------------------------------------------------------------------- -------------- --------------- ------------- ------------- ------------- ---------------
  **Treatments**                                                                                                                                                                     
  STEMI                                                                                                        **−0.3**         −0.1           −0.3          −0.3          −0.4           −0.6
  NSTEACS                                                                                                      **0.8**           0.8            0.7           0.7           0.7            1.0
  Secondary prevention post MI                                                                                 **9.2**           8.7            9.4           8.9           9.4            9.7
  Secondary prevention post revasc                                                                             **1.5**           1.5            1.5           1.5           1.5            1.7
  Chronic stable CAD                                                                                           **12.7**         11.6           12.2          12.2          13.3           14.6
  Heart failure in the hospital                                                                                **0.7**           0.6            0.6           0.6           0.8            0.8
  Heart failure in the community                                                                               **8.8**           7.7            8.4           8.8           9.4            9.8
  Hypertension treatment                                                                                       **4.7**           4.9            5.0           4.9           4.5            4.2
  Hyperlipidemia treatment (statins)                                                                           **13.9**         14.3           11.9          15.6          15.7           11.8
  **Total treatments** [a](#nt115){ref-type="table-fn"}                                                        **52.0**       **49.9**       **49.3**      **52.9**      **54.9**       **52.9**
  **Risk factors**                                                                                                                                                                   
  Smoking                                                                                                        2.7             1.3            1.8           2.3           3.2            5.6
  Diabetes                                                                                                       −7.4           −5.0           −5.3          −6.4          −7.6           −13.8
  Physical inactivity                                                                                            1.6             1.2            1.3           1.4           1.7            2.4
  Systolic blood pressure, mmHg                                                                                  29.3           25.3           26.4          27.8          31.5           36.9
  Total cholesterol, mmol/l                                                                                      5.5             3.2            6.1           3.4           4.6           11.0
  BMI                                                                                                            −1.7           −1.5           −1.6          −1.6          −1.7           −2.1
  Fruit and vegetable consumption                                                                                4.1             4.2            4.1           4.1           4.0            4.2
  **Total Risk Factors** [a](#nt115){ref-type="table-fn"}                                                      **34.1**       **28.7**       **32.7**      **31.0**      **35.7**       **44.2**
  **DPPs explained by model** [a](#nt115){ref-type="table-fn"}                                                 **86.1**       **78.6**       **82.0**      **84.0**      **90.6**       **97.1**
  **DPPs not explained by model** [a](#nt115){ref-type="table-fn"}                                             **13.9**       **21.4**       **18.0**      **16.0**       **9.4**        **2.9**
  **DPP Counts** [a](#nt115){ref-type="table-fn"} ^,^ [b](#nt116){ref-type="table-fn"}                                                                                               
  **DPPs explained by model** [a](#nt115){ref-type="table-fn"} **^,^** [b](#nt116){ref-type="table-fn"}       **32,770**      **5,777**      **6,746**     **7,012**     **6,870**      **6,367**
  - Due to treatment uptake[b](#nt116){ref-type="table-fn"}                                                  ***19,780***    ***3,670***    ***4,055***   ***4,420***   ***4,166***    ***3,471***
  - Due to risk factor change[b](#nt116){ref-type="table-fn"}                                                ***12,990***    ***2,107***    ***2,690***   ***2,591***   ***2,704***    ***2,896***
  **DPPs unexplained by model** [a](#nt115){ref-type="table-fn"} **^,^** [b](#nt116){ref-type="table-fn"}     **5,300**       **1,576**      **1,479**     **1,337**      **714**        **191**
  **Total DPPs** [a](#nt115){ref-type="table-fn"} **^,^** [b](#nt116){ref-type="table-fn"}                    **38,070**      **7,353**      **8,225**     **8,349**     **7,584**      **6,558**

Sub-totals (in rows).

DPP counts for England (column 1) have been rounded to nearest 5. All counts are in italics.

Abbreviations: CAD, coronary artery disease; IMD, index of multiple deprivation; NSTEACS, non-ST elevation acute coronary syndrome; MI, myocardial infarction; revasc, revascularisation; STEMI, ST elevation myocardial infarction.

The most substantial contribution to deaths prevented by treatments came from statin treatment for hyperlipidemia (14% of the total mortality reduction, 5%--32%), management of chronic stable coronary artery disease (13%; 10%--17%), and secondary prevention following myocardial infarction or revascularisation (11%; 8%--13%) ([Table 2](#pmed-1001237-t002){ref-type="table"}). Uptake rates of statins and angiotensin-converting enzyme inhibitors (ACE inhibitors) or angiotensin receptor blockers (ARB) more than doubled for secondary prevention and the management of stable coronary artery disease ([Table 5](#pmed-1001237-t005){ref-type="table"}). These two therapies together contributed some 6,340 DPPs (17%). In contrast, deaths averted due to changes in treatment uptake in hospital-based patient groups were relatively modest: contributing just 165 fewer deaths (0.5%; −1% to 3%) amongst emergency admissions for infarction and unstable angina (ST elevation myocardial infarction \[STEMI\] and non-ST elevation acute coronary syndrome \[NSTEACS\], respectively). Improved heart failure treatments in the community resulted in approximately 3,335 fewer deaths (9%; 7%--10%), with relatively modest gains (250 fewer deaths) in hospitalised patients. Furthermore, there were essentially no gradients in treatment uptake across deprivation quintiles for either hospital treatment or drugs prescribed in the community for secondary prevention and heart failure ([Table 5](#pmed-1001237-t005){ref-type="table"}).

10.1371/journal.pmed.1001237.t005

###### Percentage treatment uptake rates 2000 and 2007 for England and stratified by deprivation quintiles.
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  Treatment by Patient Groups                        Eligible Patients[a](#nt119){ref-type="table-fn"}   England    Most Affluent    IMDQ2     IMDQ3     IMDQ4    Most Deprived                                                    
  ------------------------------------------------- --------------------------------------------------- ---------- --------------- --------- --------- --------- --------------- --------- --------- --------- --------- --------- ---------
  **STEMI**                                                             **20,700**                                                                                                                                                 
  Thrombolysis                                                                                           **77.2**     **56.7**       79.4      58.6      77.9         59.5         75.4      57.1      76.2      56.0      77.4      52.5
  Aspirin                                                                                                **93.6**     **96.0**       93.6      96.6      94.7         96.3         93.1      95.4      93.2      95.6      93.4      96.4
  B-blocker                                                                                              **71.3**     **70.3**       74.8      70.9      72.3         69.1         71.0      69.8      69.6      69.5      69.9      72.4
  ACE inhibitor or ARB                                                                                   **77.2**     **76.3**       79.8      76.6      78.9         75.6         75.4      75.5      75.4      74.8      77.3      79.2
  Clopidogrel                                                                                            **27.7**     **88.5**       26.9      88.7      25.7         87.7         28.0      88.4      28.5      88.4      28.9      89.2
  Primary PCI                                                                                            **3.9**      **23.7**        2.9      24.2       3.4         21.8          3.8      23.3       4.3      24.5       4.8      24.8
  Primary CABG                                                                                           **0.1**       **0.1**        0.1       0.1       0.0          0.1          0.1       0.1       0.1       0.2       0.0       0.1
  CPR in hospital                                                                                        **11.4**      **6.6**        9.9       6.5      11.6          7.1         11.7       6.3      11.8       6.7      11.6       6.3
  **NSTEACS**                                                           **91,285**                                                                                                                                                 
  Aspirin and heparin                                                                                    **64.0**     **79.7**       67.1      79.7      65.0         80.3         66.7      79.9      65.7      80.2      57.9      78.8
  Aspirin alone                                                                                          **24.2**     **12.8**       21.5      13.5      23.9         12.3         21.5      12.7      23.5      12.6      28.9      13.1
  PG IIB/IIIA                                                                                            **6.1**       **5.8**      **9.4**   **6.2**   **7.3**      **5.8**      **6.1**   **5.1**   **4.7**   **5.2**   **4.3**   **6.8**
  **ACE inhibitor or ARB**                                                                               **66.0**     **73.2**       68.6      73.1      64.5         72.2         65.9      72.5      64.3      72.7      67.0      75.0
  B-blocker                                                                                              **63.2**     **67.6**       66.1      68.2      62.7         67.7         63.5      66.7      61.7      66.3      62.8      69.2
  Clopidogrel                                                                                            **44.3**     **86.6**       43.5      87.1      44.2         86.9         42.3      86.8      45.6      85.9      45.4      86.3
  CABG surgery                                                                                           **3.0**       **2.6**        3.5       3.4       3.2          2.7          3.2       2.6       2.9       2.3       2.5       2.1
  PCI                                                                                                    **3.1**       **6.7**        3.6       7.7       3.4          6.9          3.2       7.0       2.9       6.4       2.5       5.7
  CPR in hospital                                                                                        **5.3**       **2.3**        4.6       2.3       4.9          2.2          5.3       2.1       5.6       2.5       5.8       2.5
  **Secondary prevention post revascularisation**                       **111,930**                                                                                                                                                
  Aspirin                                                                                                **64.3**     **76.5**       58.8      73.5      63.5         76.2         62.5      76.5      65.7      76.1      71.2      80.0
  B-blocker                                                                                              **30.7**     **55.7**       29.2      52.7      30.5         55.6         29.8      56.4      31.7      56.9      32.3      56.9
  ACE inhibitor or ARB                                                                                   **30.1**     **64.2**       30.8      63.9      29.2         63.0         29.5      63.9      30.9      63.4      30.5      67.1
  Statin                                                                                                 **58.2**     **84.5**       61.7      85.1      58.2         84.6         56.3      83.9      56.3      84.8      58.7      84.2
  Warfarin                                                                                               **7.4**       **6.7**        7.9       7.2       7.3          6.6          6.7       6.5       7.1       7.1       7.9       6.1
  Rehabilitation (post CABG)                                                                             **73.0**     **73.0**       73.0      73.0      73.0         73.0         73.0      73.0      73.0      73.0      73.0      73.0
  Rehabilitation (post PTCA)                                                                             **10.0**     **20.0**       10.0      20.0      10.0         20.0         10.0      20.0      10.0      20.0      10.0      20.0
  **Secondary prevention post MI**                                      **565,595**                                                                                                                                                
  Aspirin                                                                                                **59.7**     **74.4**       56.4      72.4      60.0         74.3         59.2      74.5      58.8      74.8      63.3      75.8
  B-blocker                                                                                              **32.6**     **53.4**       34.0      54.0      34.0         54.6         31.6      53.3      32.2      52.9      31.7      52.4
  ACE inhibitor or ARB                                                                                   **31.3**     **62.0**       32.3      62.6      32.5         62.3         31.0      61.6      30.6      61.2      30.5      62.5
  Statin                                                                                                 **37.1**     **77.4**       39.8      77.9      39.5         77.8         35.9      76.6      34.7      76.6      36.2      78.1
  Warfarin                                                                                               **6.6**       **8.1**        7.7       8.3       6.7          8.9          6.5       7.9       6.2       7.7       6.2       7.6
  Rehabilitation                                                                                         **45.0**     **45.0**       45.0      45.0      45.0         45.0         45.0      45.0      45.0      45.0      45.0      45.0
  **Chronic stable CAD**                                                **984,805**                                                                                                                                                
  Aspirin in community                                                                                   **42.9**     **62.4**       38.7      57.2      42.6         61.4         44.7      64.3      42.9      63.4      45.0      65.3
  Statin in community                                                                                    **23.9**     **66.2**       25.4      63.4      24.2         65.4         23.7      66.5      23.0      66.3      23.3      69.2
  ACE inhibitor or ARB                                                                                   **19.8**     **45.7**       19.9      45.1      19.0         45.5         20.5      45.8      20.1      45.5      19.7      46.5
  CABG surgery                                                                                           **8.7**       **9.6**        8.8       9.8       8.7          9.7          9.6      10.3       8.7       9.7       7.7       8.8
  **Heart failure - hospital**                                          **24,625**                                                                                                                                                 
  ACE inhibitor                                                                                          **53.2**     **59.1**       51.8      57.6      52.1         57.9         52.7      58.6      53.4      59.4      55.2      61.4
  B-blocker                                                                                              **25.4**     **28.2**       24.3      27.0      24.5         27.2         25.0      27.8      25.6      28.5      27.1      30.1
  Spironolactone                                                                                         **20.7**     **22.9**       19.8      22.0      20.0         22.3         20.4      22.7      20.8      23.1      21.8      24.3
  Aspirin                                                                                                **59.2**     **73.9**       56.6      71.9      59.8         73.3         58.6      74.1      58.1      75.3      62.2      74.4
  **Heart failure - community**                                         **172,770**                                                                                                                                                
  ACE inhibitor or ARB                                                                                   **45.6**     **68.9**       48.2      70.2      44.5         69.3         43.4      67.8      45.9      69.2      46.6      68.4
  B-blocker                                                                                              **10.4**     **34.2**       10.7      35.1      11.2         34.6         10.8      34.9       9.4      34.2      10.1      32.4
  Spironolactone                                                                                         **3.9**      **14.5**        4.3      14.7       3.9         14.9          3.6      13.0       3.9      15.1       4.0      14.9
  Aspirin                                                                                                **38.1**     **50.4**       37.9      46.3      38.3         49.9         37.3      50.3      37.0      51.8      40.0      52.7
  **Hypertension treatment**                                          **35,280,845**                     **8.3**      **13.5**        8.3      14.0       8.2         13.8          8.6      13.9       8.2      13.0       8.3      12.7
  **Hyperlipidemia treatment**                                        **35,280,845**                     **1.1**       **9.0**        1.0       7.9       1.1          8.5          1.1       9.1       1.4      10.3       1.3       9.1

The overall treatment uptake rate is a weighted average over all age groups 25+ and both sexes.

Eligible patient numbers rounded to nearest 5.

Sub-totals (in rows) for CHD patient groups.

Abbreviations: B-blocker: beta-blocker; CABG: coronary artery bypass graft; CAD, coronary artery disease; CPR, cardiopulmonary resuscitation; IMD, index of multiple deprivation; NSTEACS, non-ST elevation acute coronary syndrome; MI, myocardial infarction; PCI, percutaneous coronary intervention; PG, platelet glycoprotein; PTCA, percutaneous transluminal coronary angioplasty; STEMI, ST elevation myocardial infarction.

Of the deaths prevented due to population-level risk factor changes, the largest contribution came from the fall in systolic blood pressure amongst those not on hypertensive medications (11,160 fewer deaths, or 29%; 18%--40%) ([Table 3](#pmed-1001237-t003){ref-type="table"}). On the other hand, gains from hypertensive medication were modest (approximately 1,800 fewer deaths \[5%; 2%--10%\]) ([Table 2](#pmed-1001237-t002){ref-type="table"}). Blood pressure falls were twice as high in women (5.4 mmHg versus 2.5 mmHg in men) but were of a similar magnitude across all deprivation quintiles ([Table 6](#pmed-1001237-t006){ref-type="table"}). Both in terms of absolute numbers and proportions, more deaths were prevented because of blood pressure falls in the most deprived quintile than in the most affluent ([Tables 3](#pmed-1001237-t003){ref-type="table"} and [4](#pmed-1001237-t004){ref-type="table"}).

10.1371/journal.pmed.1001237.t006

###### Absolute change in risk factor levels between 2000 and 2007 for England and stratified by deprivation quintiles and sex.
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  Risk Factors                                              Overall Levels   Absolute Change in Percentage Points, 2000--2007                                         
  -------------------------------------------------------- ---------------- -------------------------------------------------- ---------- ------ ------ ------ ------ ------
  **Smoking prevalence (%)**                                                                                                                                          
  Male                                                        ***27.2***                        ***23.6***                      **−3.7**   −2.6   −3.1   −3.6   −4.1   −4.8
  Female                                                      ***23.4***                        ***19.9***                      **−3.5**   −2.5   −3.0   −3.4   −4.0   −4.6
  **Diabetes prevalence (%)**                                                                                                                                         
  Male                                                        ***3.7***                         ***6.5***                       **2.8**    2.4    2.7    2.8    2.6    3.6
  Female                                                      ***2.9***                         ***4.8***                       **1.9**    1.6    1.4    1.6    2.1    2.8
  **Physical inactivity (%)**                                                                                                                                         
  Male                                                        ***80.9***                        ***74.0***                      **−6.9**   −6.9   −6.7   −6.8   −6.9   −7.2
  Female                                                      ***82.4***                        ***78.1***                      **−4.3**   −4.3   −4.2   −4.2   −4.2   −4.4
  **Systolic blood pressure (mmHg)**                                                                                                                                  
  Male                                                       ***133.1***                       ***130.6***                      **−2.5**   −2.6   −2.6   −2.5   −2.5   −2.4
  Female                                                     ***131.0***                       ***125.6***                      **−5.4**   −5.3   −5.5   −5.5   −5.5   −5.5
  **Total cholesterol (mmol/l)**                                                                                                                                      
  Male                                                        ***5.6***                         ***5.4***                       **−0.1**   −0.2   −0.2   −0.2   −0.1   −0.1
  Female                                                      ***5.7***                         ***5.5***                       **−0.2**   −0.2   −0.2   −0.2   −0.2   −0.2
  **BMI (kg/m^2^)**                                                                                                                                                   
  Male                                                        ***27.3***                        ***27.7***                      **0.4**    0.4    0.4    0.4    0.3    0.3
  Female                                                      ***26.9***                        ***27.2***                      **0.2**    0.2    0.2    0.2    0.2    0.3
  **Fruit and vegetable consumption (portions per day)**                                                                                                              
  Male                                                        ***3.4***                         ***3.7***                       **0.4**    0.4    0.4    0.4    0.4    0.3
  Female                                                      ***3.6***                         ***4.0***                       **0.4**    0.4    0.4    0.4    0.4    0.4

See [Text S1](#pmed.1001237.s001){ref-type="supplementary-material"}, Table K for weighted averages of risk factor levels for each deprivation quintile, 2000 and 2007.

England average weighted by 2007 population distribution in 10-y age bands.

IMD, index of multiple deprivation.

In contrast, the benefits attributable to statin lowering of total cholesterol levels were double those attributable to the fall in cholesterol levels in the population not on treatment (approximately 5,300 versus 2,090 fewer deaths, respectively). Between 2000 and 2007, hyperlipidemia treatment increased nine-fold across all social groups from 1% to 9% ([Table 5](#pmed-1001237-t005){ref-type="table"}). Total cholesterol levels fell marginally more in women than men and by a similar magnitude across deprivation quintiles ([Table 6](#pmed-1001237-t006){ref-type="table"}). Thus, while the proportionate fall in deaths attributable to cholesterol reduction in the general population was similar across quintiles, in absolute terms more deaths were prevented in the most deprived quintiles ([Table 3](#pmed-1001237-t003){ref-type="table"}).

Favourable trends in smoking, fruit and vegetable consumption, and physical activity were modest; together only contributing about 3,195 fewer deaths, or 8% (2%--18%) of the overall mortality fall ([Table 2](#pmed-1001237-t002){ref-type="table"}). Smoking prevalence declined in men and women by a similar amount (4%); however, there was a clear social gradient with larger absolute falls in smoking prevalence in more deprived quintiles ([Table 6](#pmed-1001237-t006){ref-type="table"}). Furthermore, levels of smoking still remained twice as high in the most deprived compared to affluent groups ([Text S1](#pmed.1001237.s001){ref-type="supplementary-material"}, Table K). Physical inactivity fell more in men (7%) than women (4%) across all deprivation quintiles; however, three in four adults remained classed as inactive in every quintile.

Mortality gains due to positive trends in smoking, fruit and vegetable consumption, and physical activity risk factors were negated by increases in BMI and diabetes (together contributing 3,460 additional deaths, equivalent to an 9% increase in mortality (−17% to −3%) ([Table 3](#pmed-1001237-t003){ref-type="table"}). Even over the relatively short period of this analysis, the social gradient in diabetes became more pronounced resulting in three times as many additional diabetes-related deaths in the most deprived quintile compared with the most affluent.

Model Fit {#s3a}
---------

The percentage unexplained by the model varied by age, sex, and SECs. The model fit was generally good overall and in women and men living in the most deprived areas ([Text S1](#pmed.1001237.s001){ref-type="supplementary-material"}, Table L.3). However, the fit was least good in affluent quintiles, with the 95% uncertainty limits around the DPPs explained by the model (5,777; 4,134--7,420) just overlapping with the number of observed DPPs (7,353). Model fit was also better for women than men (see [Text S1](#pmed.1001237.s001){ref-type="supplementary-material"}, Figure L.1).

Discussion {#s4}
==========

Between 2000 and 2007, English CHD mortality rates fell by an impressive 36%, resulting in approximately 38,000 fewer CHD deaths in 2007. However the relative mortality inequalities between rich and poor persisted and even increased slightly over this period. This study is the first, to our knowledge, to analyse the socioeconomic components concealed within the overall mortality reductions attributable specifically to risk factor trends and to evidence-based treatments. By using deprivation scores for area of residence as a unified marker of SECs across all relevant large databases of population health and health service use in England, the study had adequate statistical size to quantify the impact of changes in risk factors and treatments within socioeconomic groups, even over a relatively short period of 7 y. Understanding these recent trends, and their socially divergent trajectories, will be crucial to planning the most effective and equitable future strategies to prevent cardiovascular disease and reduce inequalities.

Main Findings {#s4a}
-------------

Approximately half the fall in CHD mortality was attributable to increased medical therapies. These benefits largely reflected a doubling of drug use for community patients with chronic disease (who represent the largest CHD burden). In contrast, the contribution of medical interventions in hospital was relatively modest. Firstly, because the numbers of patients admitted to hospital with acute disease were much smaller. Secondly, because few new treatments were introduced after 2000 other than clopidogrel and primary angioplasty. And thirdly, the uptake rates for existing hospital-based treatments were already close to maximum levels in 2000. The age-specific prevalence of CHD is socially graded. With similar levels of uptake of treatments across socioeconomic quintiles in both base and final years, this meant that the benefits of increased treatment were distributed remarkably evenly across social groups, which suggests a fairly equitable distribution of therapies across the NHS.

Reductions in major cardiovascular risk factors explained over two-fifths of the fall in CHD mortality (43%). However, the net benefit was much smaller (approximately 34%) because adverse trends in BMI and diabetes potentially increased mortality by some 9%.

The single largest contribution to the overall CHD mortality decrease came from population falls in blood pressure [@pmed.1001237-TunstallPedoe1] with relatively small gains from hypertension therapies. Furthermore, reductions were similar across social groups. This is therefore entirely consistent with recent UK population-wide reductions in salt intake [@pmed.1001237-UK3], and with recent encouraging trends in other wealthy counties [@pmed.1001237-Danaei1].

Small increases in fruit and vegetable consumption and physical activity were seen across all social groups. Furthermore, moderate declines in smoking levels were actually greater in deprived areas. This may reflect the benefit of cumulative tobacco control policies since 2000, reinforced by the targeting of cessation services in deprived areas [@pmed.1001237-Bauld1].

However, after excluding the effect of statin therapy, the decline in cholesterol levels in the wider population was modest. This finding may well reflect a failure to implement more effective dietary policies [@pmed.1001237-National1]. Particularly worrying was the approximately 3,500 additional deaths attributable to the continuing rises in diabetes and BMI. This number is consistent with recent Foresight analyses and represents a further warning to policy makers [@pmed.1001237-Foresight1].

The absolute gap in CHD mortality between the most affluent and most deprived groups narrowed over the period of our study, however relative inequalities widened. This was unlikely to be due to differential treatment of diagnosed patients because levels of uptake of evidence-based therapies were similar for all groups. The pace of fall in mortality in the most affluent groups was faster; but changes in risk factor levels could not explain about 20% of this fall. By contrast, in the most deprived quintile, changes in risk factor levels explained almost all of the remaining CHD mortality fall after accounting for deaths averted due to increase in treatment uptake rates. Perhaps the most likely explanation for this difference is a social gradient in effect modification. Thus, the current model assumed that the mortality decrease per unit change in risk factor was similar across deprivation quintiles. However, the benefits of a specific decrease in blood pressure or cholesterol may be disproportionately higher in more affluent groups, perhaps reflecting synergy with other positive trends [@pmed.1001237-Yusuf1]. A recent cohort analysis found that even if four classic risk factors---blood pressure, cholesterol, smoking, and diabetes---were to be completely eliminated in middle-aged men, relative inequalities in CHD mortality between those in low and high employment grades would persist despite a 70% reduction in absolute mortality differences [@pmed.1001237-Kivimki1]. Furthermore we do not have many estimates of the cumulative benefit associated with a lifetime of low risk. For example, the Finnish Public Sector Study found that a marked socioeconomic gradient in absolute risk of CHD mortality persisted even in a low-risk subgroup that had never smoked, were not obese or physically inactive, and who consumed moderate amounts of alcohol [@pmed.1001237-Kivimki2].

Alternative explanations for the fraction of the mortality fall unexplained by the model include the possible omission of more "upstream" risks such as psychosocial stress, which might differentially benefit affluent groups [@pmed.1001237-Yusuf1],[@pmed.1001237-Harald1]. Differential levels of adherence to prescribed medications may also play a role; however, this is a relatively under-researched area without clear-cut evidence to support or refute the existence of systematic social gradients [@pmed.1001237-National2]--[@pmed.1001237-Schz1]. We also tested the impact of varying adherence rates differentially on the DPPs explained. However, varying adherence rates in this way had a limited effect on reducing the gradient in the proportion unexplained. Finally, measurement error may contribute; Health Survey estimates of risk factor trends by deprivation quintiles may lack precision because of small samples and differential response rates.

Comparisons with Other UK and International Studies {#s4b}
---------------------------------------------------

Compared with previous IMPACT analyses from a baseline of the 1980s [@pmed.1001237-Unal1],[@pmed.1001237-Ford1],[@pmed.1001237-Capewell2]--[@pmed.1001237-Aspelund1], models of more recent changes, for example in Ontario [@pmed.1001237-Wijeysundera1], demonstrate the growing relative contribution from improved treatments to reductions in CHD mortality. However, country-specific proportions attributable to risk factors or treatments are relative to the scale of the decline, and hence potentially misleading. Thus, although Nordic countries possess uniformly good health services, their larger absolute falls in coronary mortality mainly reflect particularly impressive decreases in major risk factors, mainly cholesterol, blood pressure and smoking, and smaller increases in obesity and diabetes [@pmed.1001237-Aspelund1],[@pmed.1001237-Leyland2].

Strengths and Limitations of This Study {#s4c}
---------------------------------------

The IMPACT model has been replicated and validated in diverse national populations. This is the first IMPACT study to quantify the socioeconomic components of the contributions of changes in treatment and risk factors to falls in coronary mortality. The main datasets used are reasonably representative of the socioeconomic distribution of the English population and large enough for reasonably accurate estimates of socioeconomic change.

However, a number of limitations should also be acknowledged. These include the use of area-level categorisation of SECs. However, area deprivation correlates well with individual socioeconomic position and may also help to capture the contextual effects of living conditions [@pmed.1001237-Laatikainen1],[@pmed.1001237-DaveySmith1].

Approximately 14% of the CHD mortality fall was not explained by the model and the uncertainty analysis also produced wide limits in the percentage explained (86%; 65%--107%). The model fit was also less good in men in affluent areas, as discussed earlier. However, the model fit was generally good overall and in women and in men living in the most deprived areas. As with all models attempting to capture complex and interacting changes, it remains possible that there were additional (unquantifiable) sources of error not captured by the uncertainty analysis.

Conclusions and Implications for Future Prevention Policies and Strategies {#s4d}
--------------------------------------------------------------------------

Approximately half of the recent substantial CHD mortality fall in England was attributable to medical therapies. Benefits were relatively even across social groups. These findings are consistent with equitable service delivery across the NHS. Treatment uptake in hospitals was close to maximum levels over the entire period, while follow-up treatment of cardiovascular patients in the community substantially improved and was equitable. This suggests the Qualities and Outcome Framework that was being implemented in general practice during the study period was an effective incentive for improving uptake overall [@pmed.1001237-Doran1].

However, the net gains from risk factor improvements were small, reflecting modest recent decreases in powerful cardiovascular risk factors such as smoking and cholesterol, and further eroded by continuing rises in BMI and diabetes. This throws a spotlight on recent UK policies for salt reduction and tobacco control (relatively effective) and healthier diets (relatively neglected). Elsewhere, the successful introduction of effective, powerful, rapid, and cost-saving policy interventions have achieved substantial reductions in the saturated fat, trans-fats, sugars, and calories hidden in processed food, takeaways, and sweetened drinks [@pmed.1001237-National1],[@pmed.1001237-Doran1],[@pmed.1001237-Zatonski1]. Mandatory interventions involving legislation, regulation, taxation, or subsidies consistently appear more effective and cost saving than voluntary schemes [@pmed.1001237-Danaei1],[@pmed.1001237-Cobiac1],[@pmed.1001237-Glantz1]. They also tend to be equitable [@pmed.1001237-Capewell1] and surprisingly rapid [@pmed.1001237-Kuulasmaa1],[@pmed.1001237-Zatonski1]. The UK now has an equally pressing need for population-wide policy interventions to effectively tackle persistent inequalities in cardiovascular mortality.

Supporting Information {#s6}
======================
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ARB

:   angiotensin receptor blocker

ACE inhibitor

:   angiotensin-converting enzyme inhibitors

BMI

:   body mass index

CHD

:   coronary heart disease

DPP

:   deaths prevented or postponed

NHS

:   National Health Service

SEC

:   socioeconomic circumstance
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